191 related articles for article (PubMed ID: 33734461)
1. Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Lehto TK; Stürenberg C; Malén A; Erickson AM; Koistinen H; Mills IG; Rannikko A; Mirtti T
Prostate; 2021 May; 81(7):368-376. PubMed ID: 33734461
[TBL] [Abstract][Full Text] [Related]
2. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
Lehto TK; Pylväläinen J; Sandeman K; Kenttämies A; Nordling S; Mills IG; Tang J; Mirtti T; Rannikko A
Int J Cancer; 2024 Mar; 154(5):926-939. PubMed ID: 37767987
[TBL] [Abstract][Full Text] [Related]
3. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.
Creed JH; Berglund AE; Rounbehler RJ; Awasthi S; Cleveland JL; Park JY; Yamoah K; Gerke TA
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):246-253. PubMed ID: 31757784
[TBL] [Abstract][Full Text] [Related]
4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
[TBL] [Abstract][Full Text] [Related]
6. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
7. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
9. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
10. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
[TBL] [Abstract][Full Text] [Related]
12. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
13. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
14. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
15. Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer genomics: comparing results from three molecular assays.
Alam S; Tortora J; Staff I; McLaughlin T; Wagner J
Can J Urol; 2019 Jun; 26(3):9758-9762. PubMed ID: 31180305
[TBL] [Abstract][Full Text] [Related]
17. Genomic testing for localized prostate cancer: where do we go from here?
Loeb S; Ross AE
Curr Opin Urol; 2017 Sep; 27(5):495-499. PubMed ID: 28661898
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
19. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
20. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
Abou-Ouf H; Alshalalfa M; Takhar M; Erho N; Donnelly B; Davicioni E; Karnes RJ; Bismar TA
J Cancer Res Clin Oncol; 2018 May; 144(5):883-891. PubMed ID: 29511883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
